Catalyst Event
Eli Lilly and Co (LLY) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
3/19/2026, 12:00:00 AM
Eli Lilly announced positive top-line results from its TRANSCEND-T2D-1 Phase 3 trial for retatrutide, a next-generation obesity and diabetes drug. The study showed significant reductions in both A1C levels and body weight in adults with type 2 diabetes, expected. High importance is estimated as positive Phase 3 results for a major drug typically result in a price impact exceeding 10%.
Korean Translation
일라이 릴리, 차세대 비만 및 당뇨병 치료제 레타트루타이드의 TRANSCEND-T2D-1 3상 임상시험에서 긍정적인 탑라인 결과를 발표함. 해당 연구는 제2형 당뇨병 성인 환자에서 당화혈색소(A1C) 수치와 체중 모두에서 유의미한 감소를 보임, 예상됨. 주요 약물의 긍정적인 3상 결과는 통상적으로 10% 이상의 주가 영향을 미치므로 중요도를 '높음'으로 예상함.
Related Recent Events
Novo Nordisk A/S (NVO) · Earnings Release
First quarter 2026 earnings release on May 6, 2026, scheduled.
5/6/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Merck & Co. is expected to release its Q1 2026 earnings results on or around April 30, 2026, before the market opens. High impact expected as earnings releases often drive price movements exceeding 10%, scheduled.
4/30/2026, 12:00:00 AM
Novartis AG (NVS) · Earnings Release
First quarter 2026 results scheduled for 2026-04-28; high impact expected as a major financial update.
4/28/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Other
The FDA has set a PDUFA target action date of April 28, 2026, for its review of the New Drug Application for doravirine/islatravir, an investigational HIV treatment. Approval typically impacts price by 5-10%, scheduled.
4/28/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Other
Quarterly dividend with an ex-dividend date of April 15, 2026, is scheduled.
4/15/2026, 12:00:00 AM
DICK'S Sporting Goods Inc (DKS) · Other
Quarterly dividend of $1.25 per share, announced on March 11, 2026, with an ex-dividend date of March 27, 2026. This represented a 3.1% increase from the prior dividend.
3/27/2026, 12:00:00 AM